Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Feb 21;46(2):167-169.
doi: 10.1016/j.immuni.2017.02.008.

Compliments of Factor H: What's in it for AMD?

Mary J Mattapallil  1 , Rachel R Caspi  2
Affiliations
Comment

Compliments of Factor H: What's in it for AMD?

Mary J Mattapallil et al. Immunity. .

Abstract

Genetic variations in complement factor H (CFH) confer greater risk for age-related macular degeneration (AMD). In this issue of Immunity, Calippe et al. (2017) uncover a non-canonical role for CFH in the inhibition of mononuclear phagocyte elimination from sub-retinal lesions, providing insight into the pathophysiology of AMD associated with CFH variants.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. CFH-CD11b Complex Binds to CD47 on Microglial Cells in the Retina, Competing with Binding of TSP1
The consequence of this interaction is inhibition of CD47 driven clearance of mononuclear phagocytes, whose role is removal of physiological waste products, promoting inflammation characteristic of AMD.
See this image and copyright information in PMC

Comment on

  • Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation.
    Calippe B, Augustin S, Beguier F, Charles-Messance H, Poupel L, Conart JB, Hu SJ, Lavalette S, Fauvet A, Rayes J, Levy O, Raoul W, Fitting C, Denèfle T, Pickering MC, Harris C, Jorieux S, Sullivan PM, Sahel JA, Karoyan P, Sapieha P, Guillonneau X, Gautier EL, Sennlaub F. Calippe B, et al. Immunity. 2017 Feb 21;46(2):261-272. doi: 10.1016/j.immuni.2017.01.006. Immunity. 2017. PMID: 28228282

References

    1. Ambati J, Atkinson JP, and Gelfand BD (2013). Nat. Rev. Immunol 13, 438–451. - PMC - PubMed
    1. Calippe B, Augustin S, Beguier F, Messance HC, Poupel L, Conart J-B, Hu S, Lavalette S, Fauvet A, Rayes J, et al. (2017). Immunity 46, this issue, 261–272. - PubMed
    1. Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, and Kempen J; Eye Diseases Prevalence Research Group (2004). Arch. Ophthalmol 122, 564–572. - PubMed
    1. He S, Incardona F, Jin M, Ryan SJ, and Hinton DR (2006). Yan Ke Xue Bao 22, 265–274. - PubMed
    1. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, et al. (2005). Science 308, 385–389. - PMC - PubMed

Substances